San Francisco — November 14, 2022 — Phizzle, a market leader in IoT software, launched today on the StartEngine investment community as the company looks to expand beyond its recent customer successes and gain access to growth capital.
"We have a recurring revenue contract with a F75 pharmaceutical leader and we're excited to build on our opportunity through the StartEngine investment community," said Stephen Peary, Phizzle's CFO. "Less than 1% of the scientific lab instruments in the world are connected to a cloud solution and our software is at the forefront of this exciting market transition."
Phizzle's software platform provides large-scale Pharma companies the means to digitize drug production data from scientific lab instruments, which are integral to ensuring the safety and efficacy of cancer drugs and other FDA-regulated prescription medications. On a global scale, the installed base of scientific lab instruments exceeds 1 million units across Pharma, life sciences, clean manufacturing, food production, medical environments, and office buildings.
"Our software platform is the first and only in the industry to operate multiple types and brands of scientific instruments with a single user interface via the cloud. We're driving a breakthrough in productivity and cost-savings resulting from fewer human-caused data errors in pharmaceutical drug production." — Michael Patrick, Chief Innovation Officer, Phizzle
Phizzle's system is also FDA-compliant in its use case, an important differentiator and barrier to entry. "Our micro services-based software platform is the core of our innovation, but process innovation is equally important in FDA-regulated markets," said Patrick. "Our patents and patents-pending further cement our differentiation."
In order to be compliant with regulations and safety standards, Pharma manufacturers rely on a variety of scientific instruments — including particle counters, balances, pH meters, and other equipment spanning decades of different makes and models — to monitor the manufacturing of pharmaceuticals under FDA-regulated processes.
"Our customers produce drugs that save lives," said CFO Peary. "We're excited to help improve the quality of data by reducing human error from manual testing and look forward to expanding beyond Pharma to adjacencies using the same lab instruments under similar regulated conditions, like keeping our food safe and the air our kids breathe in schools clean."
Learn more about Phizzle on StartEngine →
About Phizzle's EDGMaker Platform
Phizzle's EDGMaker is the world's first and only scientific instrument platform to centrally manage drug production data. Our technology is unlocking the manufacturing potential of the pharmaceutical industry by bringing data standardization, instrument automation, and FDA-compliant digital record-keeping to critical drug production.
About StartEngine
One of the largest equity crowdfunding platforms in the U.S., led by Activision Co-Founder Howard Marks and advised by Kevin O'Leary, StartEngine launched in 2015 with the mission to help entrepreneurs achieve their dreams, while enabling everyday people access to private investment opportunities. To date, over $650 million has been raised for startups and alternative assets on the StartEngine platform from more than 1 million users. Learn more at startengine.com